Brind.

BTIG maintained a Buy rating on Denali Therapeutics on July 16, 2025.

1 report, 1 independent Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BTIG maintained a Buy rating on Denali Therapeutics on July 16, 2025.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyBTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released o